News

MS Views and News (MSVN), a non-profit organization that works to improve education, advocacy and service to empower and enhance the quality of life of patients who suffer from multiple sclerosis (MS), has announced it will offer a series of educational events on different topics throughout the month of July in…

MediciNova, Inc., a biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs, recently announced that the ongoing clinical trial of MN-166 (ibudilast) in patients with progressive multiple sclerosis (progressive MS) has finished the randomization of 255 patients, exceeding the…

Adamas Pharmaceuticals, Inc., a specialty pharmaceutical company developing therapies for chronic disorders of the central nervous system, recently announced the beginning of a Phase 2 study that will assess the efficacy of amantadine HCl (ADS-5102) in patients with a diagnosis of multiple sclerosis (MS) who suffer from walking impairments. “We are…

With 26 states plus the District of Columbia now allowing medical marijuana use, according to a recent North American Research Committee on Multiple Sclerosis (NARCOMS) survey, many people with multiple sclerosis are considering the herb as a therapeutic option. NARCOMS is a research program that allows people with Multiple Sclerosis…

The Multiple Sclerosis Association of America (MSAA) has updated its smartphone app My MS Manager with several new features. My MS Manager, a first-of-its kind mobile phone app supporting both Apple’s iPhone (iOS 7.0 or later) and Android mobile devices (also works with iPads, iPod touch, and Android…

RedHill Biopharma Ltd. enrolled the final patient for its Phase IIa, proof-of-concept study testing RHB-104 in patients with relapsing remitting multiple sclerosis (RRMS) who test positive for Mycobacterium avium subsp. paratuberculosis (MAP). RedHill is evaluating RHB-104 as an add-on therapy to interferon beta-1a for a treatment…

In a recent review published in the journal Seminars in Arthritis and Rheumatism, German researchers explored the complexity of interwoven pathways of osteopenia, and how it relates to diseases such as MS. Osteopenia is a bone condition characterized by a decreased density of bone, which leads to bone…

A study recently published in the journal PLoS One compared the use of a specific treatment based on interferon beta-1a with other approved injectable therapies in patients with relapsing-remitting multiple sclerosis (RRMS). The study is entitled “A Network Meta-Analysis of Efficacy and Evaluation of…

In a recent meta-analysis published in the International Journal of Molecular Sciences, a team of researchers found evidence regarding the association between specific polymorphisms of the gene CD24 and MS using a method that combined data from case-control studies with family-based data. Multiple sclerosis (MS) is a chronic and…

Researchers at the Don C. Gnocchi Foundation and the University of Milano in Italy recently discovered that the levels of a specific RNA molecule vary in patients with multiple sclerosis (MS) according to their disease stage and clinical progression. The study was published in the…

Researchers at Monash University and the MIMR-PHI Institute of Medical Research in Australia recently proposed that specific human stem cells with immunomodulatory properties represent a new promising therapeutic strategy for diseases like multiple sclerosis (MS). The study was published in the Journal of Neuroinflammation and…

UK-based MS Trust has announced the launch of new awards designed to distinguish healthcare professionals that are committed to treating and changing the lives of patients who suffer from multiple sclerosis (MS). The QuDos Awards are currently open for nominations and will feature ten different categories. The QuDoS in MS Awards –…

An exciting new discovery has turned the medical world upside down, and could have important implications for the treatment of multiple sclerosis (MS). It turns out that previously undiscovered vessels exist that connect the nervous system and immune system directly. The study, titled “Structural and functional features…

Reality TV star Jack Osbourne has partnered with Teva Pharmaceutical Industries Ltd. to launch a new website as part of a three-year campaign called You Don’t Know Jack About MS. The site can be viewed here: www.youdontknowjackaboutms.com. The campaign is meant to raise awareness about…

Neuromyelitis optica (NMO), a rare autoimmune disorder often mistaken for multiple sclerosis, is similar in that it is characterized by myelin destruction in the optic nerves and spinal cord. In contrast to multiple sclerosis, as reported by the Transverse Myelitis Association, NMO does not initially affect…

In a recent study published in The Journal of Immunology, researchers from a Northwestern Medicine lab discovered a potential clue about why women are more likely than men to develop autoimmune conditions such as multiple sclerosis (MS). The researchers used a specific white blood cell, called the innate lymphoid cell,…

Most employers these days talk about having workforce diversity oriented policies that support hiring people living with disabilities and chronic diseases, but what distinguishes rhetoric from reality? What in positive, practical terms can companies do in support of helping people living with visible or invisible challenges find and keep gainful…

Compassionate Care Center of New York (CCCNY), based in Newark, Wayne County, is applying to become one of five registered commercial suppliers that will be licensed in New York State to grow medical marijuana. Licensed suppliers will serve the condition-specific palliative needs of qualifying patients with safe and accessible…

Researchers at the University of Manitoba in Canada recently conducted a study that explored the differences in lifespan and comorbidities in patients with multiple sclerosis compared to healthy individuals. The study was recently published in the journal Neurology and is entitled “Effect of comorbidity…

World MS Day is celebrated on May 27 as a day dedicated to those who suffer from multiple sclerosis (MS). In order to mark the occasion, organizations, companies, advocates, and communities are hosting events throughout the world to share inspiring stories, raise awareness about the disease and campaign to support both patients…

A new study confirmed that depression and chronic fatigue often occur in multiple sclerosis (MS); and in a related condition known as neuromyelitis optica (NMO). NMO is similar to MS because myelin–the fatty substance that insulates nerve cells and helps them to communicate–is also lost. In NMO the myelin deteriorates mostly…

A new robotic device could help people with all types of paralysis, including patients with multiple sclerosis. Erik Sorto is the first person to benefit from the device. Paralyzed at age 21 from a gunshot wound, he is now able to move his robotic arm through the power of his own…

Canadian province Prince Edward Island (PEI) has approved the inclusion of Aubagio (teriflunomide) 14 mg in the PEI Pharmacare’s provincial drug formulary. This means that the drug developed and commercialized by Genzyme is now financially supported by the state as a first-line oral tablet to treat patients who…

Exploratory research conducted at Virginia Commonwealth University and the University of Illinois at Chicago may translate into a new therapeutic agent to treat progressive multiple sclerosis. Researchers in the laboratories of Dr. Jefferey L. Dupree and Dr. Douglas L. Feinstein tested a new compound in mice with induced multiple sclerosis…

The needs of patients who suffer from progressive multiple sclerosis (MS) will be addressed in a presentation hosted by Alan Thompson, MD, FRCP, from the University College London (UCL) during the Donald Paty Memorial Lecture. The Lecture will take place during the Consortium of Multiple Sclerosis Centers (CMSC) 29th Annual…

Researchers in the Department of Immunology at St. Jude Children’s Research Hospital in Memphis were able to identify a faulty “brake” in immune cells which may be involved in the inflammation triggering multiple sclerosis (MS). This brake is believed to be able to control inflammation, offering the potential for the development of new…

A new study recently published in the journal Annals of Neurology revealed a potential new therapeutic strategy to halt multiple sclerosis (MS) disease progression. The study is entitled “Melanoma cell adhesion molecule–positive CD8 T lymphocytes mediate central nervous system inflammation” and was led by…

Results from the BENEFIT11 trial indicate that early treatment with IFNB-1b leads to improvements in cognition and fatigue in the long-term, as well as sustained employment and favorable magnetic resonance imaging (MRI) outcomes, measured at the 11-year mark. Supported by Bayer HealthCare Pharmaceuticals, the study, titled “Long-term Impact of Early MS Treatment with…

This week, Belgian-based biopharmaceutical company Ablynx announced they have entered into an exclusive research collaboration with Genzyme, a Sanofi company, to investigate the use of Nanobodies as part of a targeted therapeutic strategy for multiple sclerosis (MS).  The research will utilize Genzyme’s early-stage MS research programs involving neuroprotection…

The 4th International MS Patient Summit, which will be held on May 22 in Rome, Italy, will explore feedback from patients who suffer from multiple sclerosis (MS) in an effort to increase knowledge of the disease and, hopefully, improve treatments. Kaz Aston, the conference moderator, is an MS patient herself who was diagnosed with the…